Hennion & Walsh Asset Management Inc. Invests $567,000 in SOPHiA GENETICS SA $SOPH

Hennion & Walsh Asset Management Inc. bought a new stake in SOPHiA GENETICS SA (NASDAQ:SOPH) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 98,347 shares of the company’s stock, valued at approximately $567,000. Hennion & Walsh Asset Management Inc. owned approximately 0.12% of SOPHiA GENETICS at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sei Investments Co. bought a new position in shares of SOPHiA GENETICS during the 1st quarter worth approximately $1,772,000. 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS in the 4th quarter valued at $973,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS in the 4th quarter valued at $2,009,000. Hodges Capital Management Inc. acquired a new stake in SOPHiA GENETICS during the 1st quarter valued at $2,157,000. Finally, XTX Topco Ltd acquired a new stake in SOPHiA GENETICS during the 4th quarter valued at $55,000. 31.59% of the stock is owned by institutional investors.

Insider Transactions at SOPHiA GENETICS

In other news, insider Zhenyu Xu sold 17,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $7.29, for a total value of $123,930.00. Following the sale, the insider directly owned 590,887 shares in the company, valued at approximately $4,307,566.23. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jurgi Camblong sold 50,069 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20. Following the transaction, the chief executive officer owned 3,601,493 shares of the company’s stock, valued at approximately $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 318,592 shares of company stock valued at $1,952,315. 4.88% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on SOPH. BTIG Research upped their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Trading Down 1.6%

Shares of SOPHiA GENETICS stock opened at $7.50 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a 12-month low of $3.10 and a 12-month high of $7.88. The company has a market capitalization of $629.17 million, a price-to-earnings ratio of -6.52 and a beta of 0.96. The firm’s 50-day moving average price is $5.89 and its two-hundred day moving average price is $5.23.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. On average, analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.